<DOC>
	<DOCNO>NCT00385710</DOCNO>
	<brief_summary>Progressive Supranuclear Palsy ( PSP ) relentlessly progressive neurodegenerative disorder , clinically characterize parkinsonism prominent axial involvement postural instability , bulbar symptom , supranuclear ophthalmoplegia , executive dysfunction . Abnormal neuronal glial tau aggregation affect basal ganglion selective brainstem structure result dysfunction five frontosubcortical circuit brainstem function . There effective treatment PSP . One key feature aggregation tau phosphorylation kinases glycogen synthase kinase 3b ( GSK3b ) . Recent report show valproic acid able inhibit activity GSK3b could exert neuroprotective effect inhibition . The investigator thus decide conduct control study ass putative neuroprotective effect patient PSP .</brief_summary>
	<brief_title>Trial Valproic Acid Patients With Progressive Supranuclear Palsy ( Depakine )</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Patients possible probable PSP 45 75 year age</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Progressive supranuclear palsy ( PSP )</keyword>
</DOC>